- Home
- DTIL
as 03-25-2025 11:33am EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 43.3M | IPO Year: | 2019 |
| Target Price: | $37.67 | AVG Volume (30 days): | 137.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $15.97 | Next Earning Date: | 03-26-2025 |
| Revenue: | $68,696,000 | Revenue Growth: | 40.98% |
| Revenue Growth (this year): | -70.27% | Revenue Growth (next year): | 58.46% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buehler Kevin | DTIL | Director | Mar 26 '25 | Buy | $4.67 | 4,523 | $21,122.41 | 13,235 | |
| Brown Melinda | DTIL | Director | Mar 26 '25 | Buy | $4.75 | 1,839 | $8,735.25 | 9,057 | |
| Germano Geno J | DTIL | Director | Mar 25 '25 | Buy | $5.30 | 3,250 | $17,225.00 | 11,057 | |
| Amoroso Michael | DTIL | President and CEO | Mar 21 '25 | Sell | $5.56 | 964 | $5,359.84 | 109,540 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Mar 3 '25 | Sell | $4.91 | 272 | $1,335.52 | 25,000 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Mar 3 '25 | Sell | $4.91 | 154 | $756.14 | 87,805 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Jan 20 '25 | Sell | $4.79 | 8,928 | $42,765.12 | 25,000 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Jan 20 '25 | Sell | $4.79 | 10,287 | $49,274.73 | 87,805 | |
| Amoroso Michael | DTIL | President and CEO | Jan 20 '25 | Sell | $4.67 | 36,838 | $172,033.46 | 109,540 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Business Wire
11 days ago
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
Business Wire
12 days ago
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
MT Newswires
14 days ago
Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance
Business Wire
14 days ago
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
Business Wire
a month ago
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 02/21/2025
Clinical Trials Arena
a month ago
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.